|
CA13 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.40689999994503E-06 |
| Normal-vs-Stage3 |
1.69453340248538E-12 |
| Normal-vs-Stage4 |
1.1831002844076E-10 |
| Stage1-vs-Stage2 |
2.048200E-01 |
| Stage1-vs-Stage3 |
2.617200E-01 |
| Stage1-vs-Stage4 |
9.656600E-01 |
| Stage2-vs-Stage3 |
6.577800E-01 |
| Stage2-vs-Stage4 |
3.009000E-01 |
| Stage3-vs-Stage4 |
4.277400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.40569997256301E-09 |
| Normal-vs-Asian |
7.77630004833441E-09 |
| Caucasian-vs-AfricanAmerican |
4.015300E-03 |
| Caucasian-vs-Asian |
4.515800E-01 |
| AfricanAmerican-vs-Asian |
6.398200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.10622663543836E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.784600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.64568358940187E-12 |
| Normal-vs-Age(61-80Yrs) |
3.30589999819608E-11 |
| Normal-vs-Age(81-100Yrs) |
5.103700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.044700E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.518400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.411370E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.621400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.255400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.148000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.061200E-01 |
| Classical-VS-Follicular |
2.33029999999745E-05 |
| Classical-VS-Other |
5.415000E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
4.273800E-02 |
| Tall-VS-Other |
6.890200E-01 |
| Tall-VS-Normal |
1.05899999991443E-07 |
| Follicular-VS-Other |
4.561200E-01 |
| Follicular-VS-Normal |
2.73579999998663E-06 |
| Other-VS-Normal |
2.037100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.79845027759029E-12 |
| Normal-vs-N1 |
2.50589549111169E-11 |
| N0-vs-N1 |
8.360200E-02 |
|
|
